2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Melanoma
26
Neuroblastoma
25
Breast Neoplasms
20
Prostatic Neoplasms
18
Leukemia
15
Multiple Myeloma
14
Lymphoma
14
Leukemia, Myeloid, Acute
14
Glioblastoma
14
Lymphoma, Non-Hodgkin
10
Neoplasms
9
Ovarian Neoplasms
8
Neoplasm Metastasis
8
Leukemia, Lymphocytic, Chronic, B-Cell
8
Colorectal Neoplasms
8
Carcinoma, Non-Small-Cell Lung
8
Breast Neoplasms, Male
8
Myelodysplastic Syndromes
7
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
7
Glioma
7
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Fallopian Tube Neoplasms
6
Osteosarcoma
5
Hodgkin Disease
5
Carcinoma, Renal Cell
5
Brain Neoplasms
5
Uveal Melanoma
4
Recurrence
4
Rectal Neoplasms
4
Medulloblastoma
4
Interventions
Influenza Vaccines
16
trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine
2
Vaccines
2
Oseltamivir
2
FluMist
2
Cyclophosphamide
2
ziprasidone
1
vaxigrip
1
thymoglobulin
1
peginterferon alfa-2a
1
influvac
1
fludarabine
1
baloxavir
1
Zolpidem
1
Warfarin
1
Vecuronium Bromide
1
Vancomycin
1
Tranexamic Acid
1
Tobramycin
1
Starch
1
Spironolactone
1
Sevelamer
1
SARS-CoV-2 inactivated vaccines
1
Rocuronium
1
Rituximab
1
Piperacillin, Tazobactam Drug Combination
1
Pentobarbital
1
Oxycodone
1
Nivolumab
1
Nifedipine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Influenza, Human
×
Granulocyte-Macrophage Colony-Stimulating Factor
×
Clear all
NCT03396575
2025-10-29
BRAVO
University of Florida
Phase 1
Terminated
11 enrolled